Neuropsychiatric side-effects of interferon alfa therapy for hepatitis C and their management: A review

Saudi Journal of Gastroenterology

Volumn 12, Issue 2, 2006, Pages 59-67

  Al Huthail, Yaser R ^a,b  

^a KING KHALID UNIVERSITY HOSPITAL   (Saudi Arabia)

^b NONE   (Saudi Arabia)

Author keywords

Depression; Interferon; Neuropsychiatric side effects; Treatment

Indexed keywords

EID: 34948844527     PISSN: 13193767     EISSN: None     Source Type: Journal    
DOI: 10.4103/1319-3767.27847     Document Type: Review

References (116)

1. Scalori A, Pozzi M, Bellia V, Apale P, Santamaria G, Bordoni T et al. Interferon-induced depression: prevalence and management. Dig Liver Dis 2005; 37:102-107.
2. Dieperink E, Willenbring M, Ho SB. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review. Am J Psychiatry 2000; 157(6):867-876.
3. Bacon BR. Managing hepatitis C 1. Am J Manag Care 2004; 10(2 Suppl):S30-S40.
4. Marsano LS, Pena LR. The interaction of alcoholic liver disease and hepatitis C 1. Hepatogastroenterology 1998; 45(20):331-339.
5. Corrao G, Carle F, Lepore AR, Zepponi E, Galatola G, Di Orio F. Interaction between alcohol consumption and positivity for antibodies to hepatitis C virus on the risk of liver cirrhosis: a case-control study. Provincial Group for the Study of Chronic Liver Disease 1. Eur J Epidemiol 1992; 8(5):634-639.
6. Williams IT, Sabin K, Fleenor M, Judson F, Mottram K, Poujade J et al. Current patterns of hepatitis C virus transmission in the United States: the role of drugs and sex. Hepatology 1998; 28:497.
7. McDonald EM, Mann AH, Thomas HC. Interferons as mediators of psychiatric morbidity. An investigation in a trial of recombinant alpha-interferon in hepatitis-B carriers 1. Lancet 1987; 2(8569):1175-1178.
8. Smedley H, Katrak M, Sikora K, Wheeler T. Neurological effects of recombinant human interferon 1. Br Med J (Clin Res Ed) 1983; 286(6361):262-264.
9. Capuron L, Gumnick JF, Musselman DL, Lawson DH, Reemsnyder A, Nemeroff CB et al. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions 1. Neuropsychopharmacology 2002; 26(5):643-652.
10. Greenberg DB, Jonasch E, Gadd MA, Ryan BF, Everett JR, Sober AJ et al. Adjuvant therapy of melanoma with interferonalpha-2b is associated with mania and bipolar syndromes 1. Cancer 2000; 89(2):356-362.
11. Valentine AD, Meyers CA, Kling MA, Richelson E, Hauser P. Mood and cognitive side effects of interferon-alpha therapy 1. Semin Oncol 1998; 25(1 Suppl 1):39-47.
12. Capuron L, Ravaud A, Dantzer R. Timing and specificity of the cognitive changes induced by interleukin-2 and interferon-alpha treatments in cancer patients 1. Psychosom Med 2001; 63(3):376-386.
13. Fried MW. Side effects of therapy of hepatitis C and their management 1. Hepatology 2002; 36(5 Suppl 1):S237-S244.
14. Janssen HL, Brouwer JT, van der Mast RC, Schalm SW. Suicide associated with alfa-interferon therapy for chronic viral hepatitis 1. J Hepatol 1994; 21(2):241-243.
15. Renault PF, Hoofnagle JH, Park Y, Mullen KD, Peters M, Jones DB et al. Psychiatric complications of long-term interferon alfa therapy 1. Arch Intern Med 1987; 147(9):1577-1580.
16. Horsmans Y. Chronic hepatitis C, depression and interferon 1. J Hepatol 2005; 42(6):788-789.
17. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial 1. Lancet 2001; 358(9286):958-965.
18. Dieperink E, Ho SB, Thuras P, Willenbring ML. A prospective study of neuropsychiatric symptoms associated with interferonalpha-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics 2003; 44(2):104-112.
19. Horikawa N, Yamazaki T, Izumi N, Uchihara M. Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study 1. Gen Hosp Psychiatry 2003; 25(1):34-38.
20. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr. et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection 1. N Engl J Med 2002; 347(13):975-982.
21. Otsubo T, Miyaoka H, Kamijima K, Onuki M, Ishii M, Mitamura K. [Depression during interferon therapy in chronic hepatitis C patients-a prospective study] 1. Seishin Shinkeigaku Zasshi 1997; 99(3):101-127.
22. Farrell GC. Therapy of hepatitis C: interferon alfa-n1 trials 1. Hepatology 1997; 26(3 Suppl 1):96S-100S.
23. Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M et al. Side effects of high-dose interferon therapy for chronic hepatitis C 1. J Hepatol 1996; 25(3):283-291.
24. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group 1. N Engl J Med 1998; 339(21):1485-1492.
25. Weiss K. Safety profile of interferon-alpha therapy 1. Semin Oncol 1998; 25(1 Suppl 1):9-13.
26. Schiff ER, Ozden N. Hepatitis C and alcohol 1. Alcohol Res Health 2003; 27(3):232-239.
27. Hauser P. Neuropsychiatric side effects of HCV therapy and their treatment: focus on IFN alpha-induced depression 1. Gastroenterol Clin North Am 2004; 33(1 Suppl):S35-S50.
28. Beratis S, Katrivanou A, Georgiou S, Monastirli A, Pasmatzi E, Gourzis P et al. Major depression and risk of depressive symptomatology associated with short-term and low-dose interferon-alpha treatment 1. J Psychosom Res 2005; 58(1):15-18.
29. Raison CL, Demetrashvili M, Capuron L, Miller AH. Neuropsychiatric adverse effects of interferon-alpha: recognition and management 1. CNS Drugs 2005; 19(2):105-123.
30. Reichenberg A, Gorman JM, Dieterich DT. Interferoninduced depression and cognitive impairment in hepatitis C virus patients: a 72 week prospective study 1. AIDS 2005; 19 Suppl 3:S174-S178.
31. Reimer J, Backmund M, Haasen C. New psychiatric and psychological aspects of diagnosis and treatment of hepatitis C and relevance for opiate dependence. Current Opinion in Psychiatry 2005; 18:678-683.
32. Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa 1. N Engl J Med 2001; 344(13):961-966.
33. Miyaoka H, Otsubo T, Kamijima K, Ishii M, Onuki M, Mitamura K. Depression from interferon therapy in patients with hepatitis C 1. Am J Psychiatry 1999; 156(7):1120.
34. Capuron L, Ravaud A. Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state 1. N Engl J Med 1999; 340(17):1370.
35. Eysenck HJ, Eysenck SBG. Eysenck Personality Questionnaire Manual. Educational and Industrial Testing Service, 1975.
36. Scalori A, Apale P, Panizzuti F, Mascoli N, Pioltelli P, Pozzi M et al. Depression during interferon therapy for chronic viral hepatitis: early identification of patients at risk by means of a computerized test 1. Eur J Gastroenterol Hepatol 2000; 12(5):505-509.
37. Schaefer M, Schmidt F, Horn M, Schmid-Wendtner MH, Volkenandt M. Depression during treatment with interferon alpha 1. Psychosomatics 2004; 45(2):176.
38. Raison CL, Borisov AS, Broadwell SD, Capuron L, Woolwine BJ, Jacobson IM et al. Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction 1. J Clin Psychiatry 2005; 66(1):41-48.
39. Pariante CM, Orru MG, Baita A, Farci MG, Carpiniello B. Treatment with interferon-alpha in patients with chronic hepatitis and mood or anxiety disorders 1. Lancet 1999; 354(9173):131-132.
40. Mulder RT, Ang M, Chapman B, Ross A, Stevens IF, Edgar C. Interferon treatment is not associated with a worsening of psychiatric symptoms in patients with hepatitis C 1. J Gastroenterol Hepatol 2000; 15(3):300-303.
41. Schaefer M, Schmidt F, Folwaczny C, Lorenz R, Martin G, Schindlbeck N et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups 1. Hepatology 2003; 37(2):443-451.
42. Van Thiel DH, Friedlander L, Molloy PJ, Fagiuoli S, Kania RJ, Caraceni P. Interferon-alpha can be used successfully in patients with hepatitis C viruspositive chronic hepatitis who have a psychiatric illness 1. Eur J Gastroenterol Hepatol 1995; 7(2):165-168.
43. Malaguarnera M, Di F, I, Restuccia S, Pistone G, Ferlito L, Rampello L. Interferon alpha-induced depression in chronic hepatitis C patients: comparison between different types of interferon alpha 1. Neuropsychobiology 1998; 37(2):93-97.
44. Fukunishi K, Tanaka H, Maruyama J, Takahashi H, Kitagishi H, Ueshima T et al. Burns in a suicide attempt related to psychiatric side effects of interferon 1. Burns 1998; 24(6):581-583.
45. Bourat L, Larrey D, Michel H. [Attempted suicide during treatment of chronic viral hepatitis C with interferon. Apropos of 2 cases] 1. Gastroenterol Clin Biol 1995; 19(12):1063.
46. Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon 1. J Hepatol 1996; 24(1):38-47.
47. Rifflet H, Vuillemin E, Oberti F, Duverger P, Laine P, Garre JB et al. [Suicidal impulses in patients with chronic viral hepatitis C during or after therapy with interferon alpha] 1. Gastroenterol Clin Biol 1998; 22(3):353-357.
48. Vesikari T, Nuutila A, Cantell K. Neurologic sequelae following interferon therapy of juvenile laryngeal papilloma 1. Acta Paediatr Scand 1988; 77(4):619-622.
49. Bernsen PL, Wong Chung RE, Vingerhoets HM, Janssen JT. Bilateral neuralgic amyotrophy induced by interferon treatment 1. Arch Neurol 1988; 45(4):449-451.
50. Meyers CA, Scheibel RS, Forman AD. Persistent neurotoxicity of systemically administered interferon-alpha 1. Neurology 1991; 41(5):672-676.
51. Schafer M, Schmidt F, Amann B, Schlosser S, Loeschke K, Grunze H. Adding low-dose antidepressants to interferon alpha treatment for chronic hepatitis C improved psychiatric tolerability in a patient with schizoaffective psychosis 1. Neuropsychobiology 2000; 42 Suppl 1:43-45.
52. Maunder RG, Hunter JJ, Feinman SV. Interferon treatment of hepatitis C associated with symptoms of PTSD 1. Psychosomatics 1998; 39(5):461-464.
53. Schaefer M, Schwaiger M, Garkisch AS, Pich M, Hinzpeter A, Uebelhack R et al. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C 1. J Hepatol 2005; 42(6):793-798.
54. Zdilar D, Franco-Bronson K, Buchler N, Locala JA, Younossi ZM. Hepatitis C, interferon alfa, and depression 1. Hepatology 2000; 31(6):1207-1211.
55. Trask PC, Esper P, Riba M, Redman B. Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions 1. J Clin Oncol 2000; 18(11):2316-2326.
56. Altindag A, Ozbulut O, Ozen S, Ucmak H. Interferon-alpha-induced mood disorder with manic features 1. Gen Hosp Psychiatry 2001; 23(3):168-170.
57. Bonaccorso S, Marino V, Puzella A, Pasquini M, Biondi M, Artini M et al. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system 1. J Clin Psychopharmacol 2002; 22(1):86-90.
58. Capuron L, Ravaud A, Neveu PJ, Miller AH, Maes M, Dantzer R. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy 1. Mol Psychiatry 2002; 7(5):468-473.
59. Lam RW, Levitan RD, Tam EM, Yatham LN, Lamoureux S, Zis AP. L-tryptophan augmentation of light therapy in patients with seasonal affective disorder 1. Can J Psychiatry 1997; 42(3):303-306.
60. Ghadirian AM, Murphy BE, Gendron MJ. Efficacy of light versus tryptophan therapy in seasonal affective disorder 1. J Affect Disord 1998; 50(1):23-27.
61. Delgado PL, Charney DS, Price LH, Aghajanian GK, Landis H, Heninger GR. Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan 1. Arch Gen Psychiatry 1990; 47(5):411-418.
62. Benkelfat C, Ellenbogen MA, Dean P, Palmour RM, Young SN. Mood-lowering effect of tryptophan depletion. Enhanced susceptibility in young men at genetic risk for major affective disorders 1. Arch Gen Psychiatry 1994; 51(9):687-697.
63. Ellenbogen MA, Young SN, Dean P, Palmour RM, Benkelfat C. Mood response to acute tryptophan depletion in healthy volunteers: sex differences and temporal stability 1. Neuropsychopharmacology 1996; 15(5):465-474.
64. Russo S, Kema IP, Haagsma EB, Boon JC, Willemse PH, den Boer JA et al. Irritability rather than depression during interferon treatment is linked to increased tryptophan catabolism 20. Psychosom Med 2005; 67(5):773-777.
65. Hauser P, Khosla J, Aurora H, Laurin J, Kling MA, Hill J et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C 1. Mol Psychiatry 2002; 7(9):942-947.
66. Levenson JL, Fallon HJ. Fluoxetine treatment of depression caused by interferon-alpha 1. Am J Gastroenterol 1993; 88(5):760-761.
67. Gleason OC, Yates WR. Five cases of interferon-alphainduced depression treated with antidepressant therapy 1. Psychosomatics 1999; 40(6):510-512.
68. Schramm TM, Lawford BR, Macdonald GA, Cooksley WG. Sertraline treatment of interferon-alfa-induced depressive disorder 1. Med J Aust 2000; 173(7):359-361.
69. Kraus MR, Schafer A, Faller H, Csef H, Scheurlen M. Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C 1. Aliment Pharmacol Ther 2002; 16(6):1091-1099.
70. Gleason OC, Yates WR, Isbell MD, Philipsen MA. An open-label trial of citalopram for major depression in patients with hepatitis C 1. J Clin Psychiatry 2002; 63(3):194-198.
71. Corssmit EP, Heijligenberg R, Endert E, Ackermans MT, Sauerwein HP, Romijn JA. Endocrine and metabolic effects of interferon-alpha in humans 1. J Clin Endocrinol Metab 1996; 81(9):3265-3269.
72. Siever LJ, Davis KL. Overview: toward a dysregulation hypothesis of depression 1. Am J Psychiatry 1985; 142(9):1017-1031.
73. Blalock JE, Smith EM. Human leukocyte interferon (HuIFN-alpha): potent endorphin-like opioid activity 1. Biochem Biophys Res Commun 1981; 101(2):472-478.
74. Barbarino A, Colasanti S, Corsello SM, Satta MA, Della CS, Rota CA et al. Dexamethasone inhibition of interferon-alpha 2-induced stimulation of cortisol and growth hormone secretion in chronic myeloproliferative syndrome 1. J Clin Endocrinol Metab 1995; 80(4):1329-1332.
75. Nemeroff CB, Krishnan KR, Reed D, Leder R, Beam C, Dunnick NR. Adrenal gland enlargement in major depression. A computed tomographic study 1. Arch Gen Psychiatry 1992; 49(5):384-387.
76. Stokes PE, Sikes CR. The hypothalamicpituitary-adrenocortical axis in major depression 1. Endocrinol Metab Clin North Am 1988; 17(1):1-19.
77. Capuron L, Raison CL, Musselman DL, Lawson DH, Nemeroff CB, Miller AH. Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy 1. Am J Psychiatry 2003; 160(7):1342-1345.
78. Bonaccorso S, Puzella A, Marino V, Pasquini M, Biondi M, Artini M et al. Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms 1. Psychiatry Res 2001; 105(1-2):45-55.
79. Lisker-Melman M, Di Bisceglie AM, Usala SJ, Weintraub B, Murray LM, Hoofnagle JH. Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa 1. Gastroenterology 1992; 102(6):2155-2160.
80. Preziati D, La Rosa L, Covini G, Marcelli R, Rescalli S, Persani L et al. Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a 1. Eur J Endocrinol 1995; 132(5):587-593.
81. Kent S, Bluthe RM, Kelley KW, Dantzer R. Sickness behavior as a new target for drug development 1. Trends Pharmacol Sci 1992; 13(1):24-28.
82. Taylor JL, Grossberg SE. The effects of interferonalpha on the production and action of other cytokines 1. Semin Oncol 1998; 25(1 Suppl 1):23-29.
83. Licinio J, Kling MA, Hauser P. Cytokines and brain function: relevance to interferon-alpha-induced mood and cognitive changes 1. Semin Oncol 1998; 25(1 Suppl 1):30-38.
84. Matthews SC, Paulus MP, Dimsdale JE. Contribution of functional neuroimaging to understanding neuropsychiatric side effects of interferon in hepatitis C 1. Psychosomatics 2004; 45(4):281-286.
85. Leigh JP, Bowlus CL, Leistikow BN, Schenker M. Costs of hepatitis C 1. Arch Intern Med 2001; 161(18):2231-2237.
86. Lerner DM, Stoudemire A, Rosenstein DL. Neuropsychiatric toxicity associated with cytokine therapies 1. Psychosomatics 1999; 40(5):428-435.
87. Maddock C, Landau S, Barry K, Maulayah P, Hotopf M, Cleare AJ et al. Psychopathological symptoms during interferon-alpha and ribavirin treatment: effects on virologic response 1. Mol Psychiatry 2005; 10(4):332-333.
88. Raison CL, Broadwell SD, Borisov AS, Manatunga AK, Capuron L, Woolwine BJ et al. Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C 1. Brain Behav Immun 2005; 19(1):23-27.
89. Kenilworth NJ. PEG-Intron (Peginterferon alfa-2b) powder for injection (package information). PMID: 16127955. 2003. 25-7-2005. Ref Type: Electronic Citation
90. Ward RP, Kugelmas M. Using pegylated interferon and ribavirin to treat patients with chronic hepatitis C 21. Am Fam Physician 2005; 72(4):655-662.
91. Benvegnu L, Chemello L, Noventa F, Fattovich G, Pontisso P, Alberti A. Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis 1. Cancer 1998; 83(5):901-909.
92. Goldman LS. Successful treatment of interferon alfa-induced mood disorder with nortriptyline 1. Psychosomatics 1994; 35(4):412-413.
93. Carvajal Garcia-Pando A, Garcia dP, Sanchez AS, Velasco MA, Rueda de Castro AM, Lucena MI. Hepatotoxicity associated with the new antidepressants 1. J Clin Psychiatry 2002; 63(2):135-137.
94. Hayasaka S, Nagaki Y, Matsumoto M, Sato S. Interferon associated retinopathy 1. Br J Ophthalmol 1998; 82(3):323-325.
95. Hejny C, Sternberg P, Lawson DH, Greiner K, Aaberg TM, Jr. Retinopathy associated with high-dose interferon alfa-2b therapy 1. Am J Ophthalmol 2001; 131(6):782-787.
96. de Abajo FJ, Rodriguez LA, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study 1. BMJ 1999; 319(7217):1106-1109.
97. van Walraven C, Mamdani MM, Wells PS, Williams JI. Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study 1. BMJ 2001; 323(7314):655-658.
98. Loftis JM, Hauser P. Safety of the treatment of interferon-alpha-induced depression 1. Psychosomatics 2003; 44(6):524-526.
99. de Lima MS, Hotoph M, Wessely S. The efficacy of drug treatments for dysthymia: a systematic review and meta-analysis 1. Psychol Med 1999; 29(6):1273-1289.
100. Toru M, Moriya H, Yamamoto K, Shimazono Y. A double-blind comparison of sulpiride with chlordiazepoxide in neurosis 1. Folia Psychiatr Neurol Jpn 1976; 30(2):153-164.
101. Dusheiko G. Side effects of alpha interferon in chronic hepatitis C 1. Hepatology 1997; 26(3 Suppl 1):112S-121S.
102. Niiranen A, Laaksonen R, Iivanainen M, Mattson K, Farkkila M, Cantell K. Behavioral assessment of patients treated with alpha-interferon 1. Acta Psychiatr Scand 1988; 78(5):622-626.
103. Nickel T, Sonntag A, Backmund M, Pollmacher T. Depression during therapy with interferon alpha-how long should an antidepressant treatment last? 1. Pharmacopsychiatry 2005; 38(2):102-104.
104. Valentine AD, Meyers CA, Talpaz M. Treatment of neurotoxic side effects of interferon-alpha with naltrexone 1. Cancer Invest 1995; 13(6):561-566.
105. Crone CC, Gabriel GM, Wise TN. Managing the neuropsychiatric side effects of interferon-based therapy for hepatitis C 1. Cleve Clin J Med 2004; 71 Suppl 3:S27-S32.
106. Onyike CU, Bonner JO, Lyketsos CG, Treisman GJ. Mania during treatment of chronic hepatitis C with pegylated interferon and ribavirin 1. Am J Psychiatry 2004; 161(3):429-435.
107. Garcia-Pares G, Domenech C, Gil M. Psychosis induced by interferon-alpha 1. Psychosomatics 2002; 43(5):428-429.
108. Monji A, Yoshida I, Tashiro K, Hayashi Y, Tashiro N. A case of persistent manic depressive illness induced by interferon-alfa in the treatment of chronic hepatitis C 1. Psychosomatics 1998; 39(6):562-564.
109. Schafer M, Boetsch T, Laakmann G. Psychosis in a methadone-substituted patient during interferon-alpha treatment of hepatitis C 1. Addiction 2000; 95(7):1101-1104.
110. Thome J, Knopf U. Acute psychosis after injection of pegylated interferon alpha-2a 1. Eur Psychiatry 2003; 18(3):142-143.
111. Byrne A, Byrne DG. The effect of exercise on depression, anxiety and other mood states: a review 1. J Psychosom Res 1993; 37(6):565-574.
112. Ademmer K, Beutel M, Bretzel R, Jaeger C, Reimer C. Suicidal ideation with IFN-alpha and ribavirin in a patient with hepatitis C 1. Psychosomatics 2001; 42(4):365-367.
113. Ho SB, Nguyen H, Tetrick LL, Opitz GA, Basara ML, Dieperink E. Influence of psychiatric diagnoses on interferon-alpha treatment for chronic hepatitis C in a veteran population 1. Am J Gastroenterol 2001; 96(1):157-164.
114. Pariante CM, Landau S, Carpiniello B. Interferon alfa-induced adverse effects in patients with a psychiatric diagnosis 1. N Engl J Med 2002; 347(2):148-149.
115. Hauser P, Soler R, Reed S, Kane R, Gulati M, Khosla J et al. Prophylactic treatment of depression induced by interferon-alpha 1. Psychosomatics 2000; 41(5):439-441.
116. Kraus MR, Schafer A, Al Taie O, Scheurlen M. Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression 1. J Viral Hepat 2005; 12(1):96-100.